You are here: Industry Insights > Lung Cancer

News List

CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC prnasia
September 13, 2021
CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines...
Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors prnasia
July 27, 2021
Hummingbird Bioscience announced that internationally renowned scientist and medical oncologist, Dr. Thomas J Lynch, Jr, MD, has been appointed to its Board as a Non-Executive Director, effective immediately.
U.S. Cancer Mortality Rates Down From 2014 to 2018 drugs
July 09, 2021
Cancer death rates in the United States continued to decline overall from 2014 to 2018, with declines accelerating for lung cancer and melanoma, according to a report published online July 8 in the Journal of the National Cancer Institute.
Glenmark gets USFDA nod for generic lung cancer drug expresspharma
June 28, 2021
Glenmark Pharmaceuticals yesterday said it has received approval from the US health regulator to market Nintedanib capsules, used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer, in the American market.
On Father's Day, Give Dad Tips to Keep Healthy drugs
June 21, 2021
Men tend to put their health care last, but Penn State Health offers some tips this Father's Day for ensuring guys stay healthy in the future.
Circle Pharma Raises $66 Million in Series C Financing PharmaSources
June 17, 2021
Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, today announced that it has raised $66 million in an oversubscribed Series C financing.
Newly Approved Lumakras (sotorasib) Fights Lung Cancer Tied to Certain Genes drugs
June 07, 2021
A newly approved lung cancer drug shows promise in improving survival in patients whose tumors carry a common and tough-to-treat genetic mutation, researchers say.
Anti-PD-L1 monoclonal antibody shows promise in lung cancer patient europeanpharmaceuticalreview
May 31, 2021
In a Phase III trial sugemalimab meaningfully improved progression free survival in patients with stage III non-small cell lung cancer (NSCLC).
FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy fda.gov
May 31, 2021
Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one
Progress Mixed in Cancer Prevention, Early Detection Measures drugs
May 24, 2021
Cancer prevention and early detection measures show mixed progress, according to a review published online May 19 in Cancer Epidemiology, Biomarkers & Prevention.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page